{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hsiao YT"],"funding":["Kobayashi Magobei Memorial Medical Promotion Foundation of Japan","Kowa Life Science Foundation","SENSHIN Medical Research Foundation","Suzuken Memorial Foundation","Cell Science Research Foundation","President's Grant for Interfaculty Collaboration Juntendo University","Japan Foundation for Applied Enzymology","Tokyo Biochemical Research Foundation","Uehara Memorial Foundation","MEXT | Japan Science and Technology Agency","Life Science Foundation of Japan","Japan Agency for Medical Research and Development","Kanae Foundation for the Promotion of Medical Science","Manpei Suzuki Diabetes Foundation","National Cerebral and Cardiovascular Center","MSD Life Science Foundation, Public Interest Incorporated Foundation","Japan Agency for Medical Research and Development (AMED)","MEXT | Japan Science and Technology Agency (JST)","Japanese Circulation Society Grant for Future-Pioneering Doctors for Basic Research","Heiwa Nakajima Foundation","Astellas Foundation for Research on Metabolic Disorders","Mochida Memorial Foundation for Medical and Pharmaceutical Research","grant from Bourbon","Japan Diabetes Foundation","MEXT | Japan Society for the Promotion of Science","Naito Foundation","Terumo Foundation for Life Sciences and Arts","MEXT | Japan Society for the Promotion of Science (JSPS)","Inamori Foundation","Japan Geriatrics Society","Daiichi Sankyo Company","Hokuto Foundation for Bioscience","Ono Medical Research Foundation","Roche Holding | Chugai Pharmaceutical","Daiichi Sankyo Foundation of Life Science"],"pagination":["4846-4869"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11535236"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["43(21)"],"pubmed_abstract":["Metabolic dysfunction-associated steatohepatitis (MASH, previously termed non-alcoholic steatohepatitis (NASH)), is a major complication of obesity that promotes fatty liver disease. MASH is characterized by progressive tissue fibrosis and sterile liver inflammation that can lead to liver cirrhosis, cancer, and death. The molecular mechanisms of fibrosis in MASH and its systemic control remain poorly understood. Here, we identified the secreted-type pro-fibrotic protein, procollagen C-endopeptidase enhancer-1 (PCPE-1), as a brown adipose tissue (BAT)-derived adipokine that promotes liver fibrosis in a murine obesity-induced MASH model. BAT-specific or systemic PCPE-1 depletion in mice ameliorated liver fibrosis, whereas, PCPE-1 gain of function in BAT enhanced hepatic fibrosis. High-calori"],"journal":["The EMBO journal"],"pubmed_title":["PCPE-1, a brown adipose tissue-derived cytokine, promotes obesity-induced liver fibrosis."],"pmcid":["PMC11535236"],"funding_grant_id":["24K18656","17K19648","23K19579","23K27602","JPMJFR200L","JP21gm5010002","16H06244","22K08215"],"pubmed_authors":["Minamino T","Morishita R","Li J","Terai S","Ishigami A","Tang JY","Walsh K","Okuda S","Shimizu I","Nakagami H","Kamimura K","Abe M","Takahashi S","Aung TM","Furihata T","Mizuno S","Hsiao YT","Yoshida Y"],"additional_accession":[]},"is_claimable":false,"name":"PCPE-1, a brown adipose tissue-derived cytokine, promotes obesity-induced liver fibrosis.","description":"Metabolic dysfunction-associated steatohepatitis (MASH, previously termed non-alcoholic steatohepatitis (NASH)), is a major complication of obesity that promotes fatty liver disease. MASH is characterized by progressive tissue fibrosis and sterile liver inflammation that can lead to liver cirrhosis, cancer, and death. The molecular mechanisms of fibrosis in MASH and its systemic control remain poorly understood. Here, we identified the secreted-type pro-fibrotic protein, procollagen C-endopeptidase enhancer-1 (PCPE-1), as a brown adipose tissue (BAT)-derived adipokine that promotes liver fibrosis in a murine obesity-induced MASH model. BAT-specific or systemic PCPE-1 depletion in mice ameliorated liver fibrosis, whereas, PCPE-1 gain of function in BAT enhanced hepatic fibrosis. High-calori","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2026-06-03T00:22:04.776Z","creation":"2025-04-04T23:31:35.372Z"},"accession":"S-EPMC11535236","cross_references":{"pubmed":["39160276"],"doi":["10.1038/s44318-024-00196-0"]}}